Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the long-term efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy as primary treatment for subfoveal myopic choroidal neovascularization (CNV).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eye (Lond)

Title: Eye (London, England)

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1476-5454

ISSN (Print): 0950-222X

Publication date (Electronic): Jul 2012

Volume: 26

Issue: 7

Affiliations

[1 ] Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, The Chinese University of Hong Kong, 147 Argyle St., Kowloon, Hong Kong, People's Republic of China. tyylai@cuhk.edu.hk

Article

Publisher Item ID: eye201297

DOI: 10.1038/eye.2012.97

PMC ID: 3396182

PubMed ID: 22595908

SO-VID: 530fdac1-4bed-49ae-baae-adc64cd8739c

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.